Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib：A Multicenter, Prospective, Phase II Clinical Study

NCT04517526 is registered in ClinicalTrials.gov with Shanghai Cancer Hospital, China as lead sponsor.

NCT NCT04517526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04517526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib：A Multicenter, Prospective, Phase II Clinical Study
Lead sponsor
Shanghai Cancer Hospital, China
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2020
Completion date
December 1, 2022
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer stage iv，egfr-mutant，tki，pd-l1，sbrt